Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Ocuphire Pharma announced the presentation of key clinical data at multiple upcoming conferences. CEO Mina Sooch will discuss company advancements at the Retina World Congress on May 12, 2022, and the H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will present masked safety data from the Phase 2b trial of APX3330 at the Retina World Congress and Clinical Trials at the Summit on May 21, 2022. Ocuphire is focused on developing therapies for eye disorders, with ongoing trials for their lead product, Nyxol, and the oral therapeutic APX3330.

Positive

• Mina Sooch will present at notable industry conferences, showcasing company advancements.
• Dr. David Lally will present safety data from the Phase 2b APX3330 trial, which could strengthen investor confidence.
• Ocuphire’s pipeline includes promising candidates Nyxol and APX3330, currently in advanced clinical trials.

Negative

• None.

FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by Mina Sooch, Founder and CEO, at the New Pathways in Retinal Diseases Panel at Retina World Congress (RWC) on May 12, 2022 and at H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will also be presenting masked safety data from Phase 2b APX3330 trial at RWC and Clinical Trials at the Summit on May 21, 2022.

Retina World Congress – May 12-15, 2022
Session:	New Pathways in Retinal Diseases
Presenter:	Mina Sooch, MBA, President and CEO
Date:	Thursday, May 12, 2022
Time:	10:20-11:00 AM EDT
Location:	Marriott Harbor Beach Hotel
Title:	Masked safety data from ZETA-1, an ongoing 24-week Phase 2 clinical trial of APX3330, an oral therapeutic being developed for the treatment of diabetic retinopathy
Presenter:	David Lally, M.D.
Type:	Poster (video format)
Location	Marriott Harbor Beach Hotel
Clinical Trials at the Summit – May 21, 2022
Title:	Phase 2 Masked Safety of Novel Oral Drug APX3330 for the Treatment of Diabetic Retinopathy
Date:	Saturday, May 21, 2022
Time:	4:10-4:40 PM PDT
Presenter:	David Lally, M.D
Location:	Hyatt Regency Lake Tahoe Resort
H.C. Wainwright Global Investment Conference – May 23-26, 2022
Title:	Ocuphire Pharma (OCUP) Company Presentation
Date:	Tuesday, May 24, 2022
Time:	2:00-2:30 PM EDT
Presenter:	Mina Sooch, MBA, President and CEO
Registration Link:	Click here

If you are interested in arranging a 1X1 meeting request or listening live to the company presentation, please contact your bank conference representative or ir@ocuphire.com.

About Ocuphire Pharma

Ocuphire is a publicly-traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting refractive and retinal indications. The company’s lead product candidate, Nyxol^® eye drops (0.75% phentolamine ophthalmic solution) is a once-daily, preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including reversal of pharmacologically-induced mydriasis (RM), presbyopia and dim light or night vision disturbances (NVD), and has been studied in 11 completed clinical trials. Ocuphire has reported positive data from MIRA-2 and MIRA-3 FDA registration trials and MIRA-4 pediatric safety trial for the treatment of RM. Ocuphire also reported positive top-line data from a Phase 2 trial of Nyxol for treatment of presbyopia, both Nyxol as a single agent and Nyxol with low-dose pilocarpine (“LDP”) 0.4% as adjunctive therapy. The company recently completed enrollment in its Phase 3 study of Nyxol for NVD (LYNX-1). Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. The company recently announced the completion of enrollment in a Phase 2b clinical trial of APX3330 to treat DR/DME (ZETA-1). Please visit www.clinicaltrials.gov to learn more about Ocuphire’s recently completed Phase 3 registration trial in RM (NCT05134974), pediatric safety study in RM (NCT05223478), Phase 3 registration trial in NVD (NCT04638660), and Phase 2b trial in DR/DME (NCT04692688). Ocuphire previously completed the first Phase 3 registration trial in RM (NCT04620213) and Phase 2 trial in presbyopia (NCT04675151). As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. For more information, visit www.ocuphire.com

Ocuphire Contacts

Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
ir@ocuphire.com
www.ocuphire.com

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com

 

FAQ

What will Mina Sooch present at the H.C. Wainwright Global Investment Conference?

Mina Sooch will present Ocuphire's company advancements on May 24, 2022.

When is the presentation of the APX3330 Phase 2b trial data?

Dr. David Lally will present the masked safety data on May 12, 2022, at the Retina World Congress.

What is the focus of Ocuphire Pharma's clinical trials?

Ocuphire is developing therapies for eye disorders, including treatments for diabetic retinopathy with APX3330 and other indications with Nyxol.

What is the significance of the Phase 2b trial for APX3330?

The Phase 2b trial data presentation may provide insights into safety and efficacy, impacting future development and investor sentiment.